Free Trial
→ Crypto’s crashing…but we’re still profiting (From Crypto Swap Profits) (Ad) Buy CLOV Stock  Free CLOV Stock Alerts

Clover Health Investments (CLOV) Financials

Clover Health Investments logo
$3.28 -0.32 (-8.89%)
As of 12:58 PM Eastern
Compare
Annual Income Statements for Clover Health Investments

Annual Income Statements for Clover Health Investments

This table shows Clover Health Investments' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -364 -136 -588 -340 -213 -43
Consolidated Net Income / (Loss)		 -364 -136 -588 -340 -213 -43
Net Income / (Loss) Continuing Operations		 -364 -136 -588 -255 -210 -46
Total Pre-Tax Income 		-364 -56 -654 -254 -210 -46
Total Revenue		 285 731 1,469 1,106 1,256 1,371
Net Interest Income / (Expense)		 -23 -36 -3.19 0.00 0.00 0.00
Total Interest Income		 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 23 36 3.19 0.00 0.00 0.00
Total Non-Interest Income		 308 767 1,472 1,106 1,256 1,371
Other Service Charges		 5.34 7.19 4.94 12 25 26
Net Realized & Unrealized Capital Gains on Investments		 -139 94 0.00 9.22 -4.73 -0.47
Premiums Earned		 457 666 799 1,085 1,236 1,345
Total Non-Interest Expense		 648 787 2,123 1,360 1,466 1,417
Salaries and Employee Benefits		 92 71 260 279 257 232
Property & Liability Insurance Claims		 454 573 1,662 900 997 1,006
Other Operating Expenses		 99 121 185 204 183 176
Depreciation Expense		 0.55 0.56 1.25 1.19 2.51 1.33
Amortization Expense		 - 21 14 0.03 0.00 0.00
Impairment Charge		 - - 0.00 0.00 16 0.00
Restructuring Charge		 - - 0.00 0.00 9.82 0.29
Other Special Charges		 2.91 0.00 - -23 0.00 0.00
Other Gains / (Losses), net		 - -80 66 0.90 -0.09 -0.05
Net Income / (Loss) Discontinued Operations		 - - - -85 -3.21 3.26
Weighted Average Basic Shares Outstanding		 87.83M 88.69M 412.92M 476.24M 482.18M 490.02M
Weighted Average Diluted Shares Outstanding		 87.83M 88.69M 412.92M 476.24M 482.18M 490.02M
Weighted Average Basic & Diluted Shares Outstanding		 - 21.18M 473.27M 479.55M 495.29M 510.91M

Quarterly Income Statements for Clover Health Investments

This table shows Clover Health Investments' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -75 -84 -73 -29 -41 -70 -19 7.41 -9.16 -22
Consolidated Net Income / (Loss)		 -75 -84 -73 -29 -41 -70 -19 7.41 -9.16 -22
Net Income / (Loss) Continuing Operations		 -75 0.74 -80 -29 -34 -68 -23 7.17 -8.79 -21
Total Pre-Tax Income 		-75 1.17 -80 -29 -34 -68 -23 7.19 -8.79 -21
Total Revenue		 855 -1,481 322 320 306 308 346 356 331 337
Total Non-Interest Income		 856 -1,482 322 320 306 308 346 356 331 337
Other Service Charges		 3.61 5.93 4.91 5.76 4.80 9.32 5.20 6.36 8.41 6.28
Premiums Earned		 268 270 317 314 301 303 342 350 323 331
Total Non-Interest Expense		 931 -1,482 402 349 340 376 370 349 340 358
Salaries and Employee Benefits		 70 69 69 62 61 65 59 55 55 63
Property & Liability Insurance Claims		 812 -1,606 275 239 236 247 265 248 250 243
Other Operating Expenses		 48 79 56 42 41 45 45 44 35 52
Depreciation Expense		 0.62 -0.84 0.28 1.00 0.56 0.67 0.32 0.33 0.34 0.34
Net Income / (Loss) Discontinued Operations		 - - 7.09 0.08 -7.85 -2.53 4.00 0.24 -0.37 -0.61
Weighted Average Basic Shares Outstanding		 477.69M 476.24M 478.81M 479.16M 480.77M 482.18M 486.37M 487.48M 490.18M 490.02M
Weighted Average Diluted Shares Outstanding		 477.69M 476.24M 478.81M 479.16M 480.77M 482.18M 486.37M 495.18M 490.18M 490.02M
Weighted Average Basic & Diluted Shares Outstanding		 477.94M 479.55M 1.05B 484.86M 487.64M 495.29M 1.05B 497.47M 501.11M 510.91M

Annual Cash Flow Statements for Clover Health Investments

This table details how cash moves in and out of Clover Health Investments' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 -7.81 25 208 -114 -9.72 18
Net Cash From Operating Activities		 -160 -118 -282 -204 -145 35
Net Cash From Continuing Operating Activities		 -160 -118 -282 -305 -35 82
Net Income / (Loss) Continuing Operations		 -364 -136 -588 -340 -213 -43
Consolidated Net Income / (Loss)		 -364 -136 -588 -340 -213 -43
Depreciation Expense		 -2.31 0.36 1.45 -0.32 -1.51 -1.19
Amortization Expense		 16 101 -52 -0.87 0.09 0.05
Non-Cash Adjustments to Reconcile Net Income		 16 17 311 39 154 114
Changes in Operating Assets and Liabilities, net		 174 -101 45 -2.36 25 12
Net Cash From Discontinued Operating Activities		 - - - 101 -110 -48
Net Cash From Investing Activities		 -182 137 -435 95 140 0.57
Net Cash From Continuing Investing Activities		 -182 137 -435 95 140 0.57
Purchase of Property, Leasehold Improvements and Equipment		 -0.02 -0.69 -0.72 -4.47 -0.58 -1.56
Purchase of Investment Securities		 -507 -174 -876 -386 -176 -201
Sale and/or Maturity of Investments		 325 312 442 485 316 203
Net Cash From Financing Activities		 334 5.84 925 -4.96 -5.07 -17
Net Cash From Continuing Financing Activities		 334 5.84 925 -4.96 -5.07 -17
Issuance of Common Equity		 0.60 1.75 290 1.40 1.15 0.90
Repurchase of Common Equity		 0.00 -0.96 -0.23 -6.36 -6.22 -18

Quarterly Cash Flow Statements for Clover Health Investments

This table details how cash moves in and out of Clover Health Investments' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 58 -197 87 120 -41 -175 32 47 33 -93
Net Cash From Operating Activities		 102 -209 79 53 -19 -258 26 45 50 -86
Net Cash From Continuing Operating Activities		 102 -310 79 33 -32 -115 26 54 50 -47
Net Income / (Loss) Continuing Operations		 -75 -84 -73 -29 -41 -70 -19 7.41 -9.16 -22
Consolidated Net Income / (Loss)		 -75 -84 -73 -29 -41 -70 -19 7.41 -9.16 -22
Depreciation Expense		 -0.08 -1.61 -2.98 2.40 -0.69 -0.24 -0.35 -0.62 -0.18 -0.04
Amortization Expense		 0.01 -0.90 - - - 0.09 - - - 0.03
Non-Cash Adjustments to Reconcile Net Income		 36 -27 56 11 33 53 21 36 28 29
Changes in Operating Assets and Liabilities, net		 141 -196 98 48 -24 -97 24 11 31 -54
Net Cash From Discontinued Operating Activities		 - - - - 14 -144 - - 0.14 -39
Net Cash From Investing Activities		 -43 13 10 66 -20 84 9.19 4.95 -12 -1.44
Net Cash From Continuing Investing Activities		 -43 13 10 66 -20 84 9.19 4.95 -12 -1.44
Purchase of Property, Leasehold Improvements and Equipment		 -0.26 -3.88 -0.25 -0.35 -0.24 0.26 -0.45 -0.40 -0.40 -0.32
Purchase of Investment Securities		 -107 -109 -68 -6.26 -68 -33 -24 -28 -102 -48
Sale and/or Maturity of Investments		 64 125 78 73 48 117 34 33 90 47
Net Cash From Financing Activities		 0.13 0.06 -2.13 -0.15 -1.96 -0.83 -3.36 -3.20 -4.67 -6.14
Net Cash From Continuing Financing Activities		 0.13 0.06 -2.13 -0.15 -1.96 -0.83 -3.36 -3.20 -4.67 -6.14
Issuance of Common Equity		 0.41 0.10 0.85 0.27 0.03 0.00 0.00 0.02 0.22 0.66
Repurchase of Common Equity		 -0.28 -0.04 -2.98 -0.42 -1.99 -0.83 -3.36 -3.22 -4.89 -6.80

Annual Balance Sheets for Clover Health Investments

This table presents Clover Health Investments' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Total Assets		 0.10 267 951 809 571 581
Cash and Due from Banks		 0.00 92 300 104 116 195
Trading Account Securities		 0.00 55 197 328 229 243
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00
Customer and Other Receivables		 - 39 48 71 64 52
Premises and Equipment, Net		 - 2.08 2.29 5.75 5.08 5.31
Unearned Premiums Asset		 - 35 35 20 22 41
Intangible Assets		 - 4.23 4.23 20 2.99 2.99
Other Assets		 0.00 40 353 160 131 42
Total Liabilities & Shareholders' Equity		 0.10 267 951 809 571 581
Total Liabilities		 0.12 433 411 452 284 240
Other Short-Term Payables		 0.12 139 184 200 261 214
Other Long-Term Liabilities		 0.00 162 19 20 23 26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.02 -613 539 357 286 341
Total Preferred & Common Equity		 -0.02 -617 535 357 286 341
Total Common Equity		 -0.02 -617 535 357 286 341
Common Stock		 0.00 412 2,154 2,319 2,461 2,577
Retained Earnings		 -0.02 -1,029 -1,617 -1,946 -2,160 -2,203
Treasury Stock		 - 0.00 -0.15 -6.51 -13 -31
Accumulated Other Comprehensive Income / (Loss)		 - 0.01 -1.93 -9.37 -2.37 -1.58

Quarterly Balance Sheets for Clover Health Investments

This table presents Clover Health Investments' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 1,558 1,454 1,258 1,060 672 674 653
Cash and Due from Banks		 383 191 310 299 208 255 288
Interest Bearing Deposits at Other Banks		 12 80 81 50 0.74 0.54 0.60
Trading Account Securities		 247 292 273 305 223 218 242
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Customer and Other Receivables		 59 57 51 52 84 67 37
Premises and Equipment, Net		 2.53 4.55 4.62 4.57 5.21 5.28 5.34
Unearned Premiums Asset		 14 70 2.06 16 71 54 21
Intangible Assets		 4.23 20 19 19 2.99 2.99 2.99
Other Assets		 836 739 516 314 77 72 56
Total Liabilities & Shareholders' Equity		 1,558 1,454 1,258 1,060 672 674 653
Total Liabilities		 1,166 1,130 927 738 379 349 311
Accrued Interest Payable		 2.00 1.86 1.75 1.67 1.62 1.49 1.35
Other Short-Term Payables		 296 329 293 279 355 323 276
Other Long-Term Liabilities		 17 20 20 19 23 25 33
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 392 323 331 322 292 325 342
Total Preferred & Common Equity		 392 323 331 322 292 325 342
Total Common Equity		 392 323 331 322 292 325 342
Common Stock		 2,281 2,359 2,395 2,428 2,490 2,518 2,546
Retained Earnings		 -1,872 -2,019 -2,048 -2,089 -2,179 -2,172 -2,181
Treasury Stock		 -6.47 -9.49 -9.91 -12 -16 -19 -24
Accumulated Other Comprehensive Income / (Loss)		 -11 -7.03 -6.72 -5.07 -2.56 -2.26 0.85

Annual Metrics and Ratios for Clover Health Investments

This table displays calculated financial ratios and metrics derived from Clover Health Investments' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 156.65% 101.03% -24.72% 13.57% 9.15%
EBITDA Growth		 0.00% 113.07% -1,641.00% 63.78% 17.18% 77.61%
EBIT Growth		 0.00% 84.58% -1,066.35% 61.13% 17.35% 78.00%
NOPAT Growth		 0.00% 84.58% -1,066.35% 61.13% 17.35% 78.00%
Net Income Growth		 0.00% 62.50% -330.93% 42.23% 37.17% 79.84%
EPS Growth		 0.00% 62.80% 7.79% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% 25.88% -138.25% 27.77% 29.06% 124.09%
Free Cash Flow Firm Growth		 0.00% 0.00% -109,338.83% 89.12% 218.37% -159.87%
Invested Capital Growth		 0.00% -216,733.99% 1,758.17% -8.68% -50.53% 19.12%
Revenue Q/Q Growth		 0.00% 0.00% 22.48% -63.37% 335.63% 2.18%
EBITDA Q/Q Growth		 0.00% 0.00% -65.68% 49.58% -46.05% 49.58%
EBIT Q/Q Growth		 0.00% 0.00% -24.21% 42.57% -48.95% 50.11%
NOPAT Q/Q Growth		 0.00% 0.00% -24.21% 42.57% -48.95% 50.11%
Net Income Q/Q Growth		 0.00% 0.00% -11.54% 23.27% 6.06% 52.94%
EPS Q/Q Growth		 0.00% 0.00% 36.61% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -7.74% -172.87% -50.78% 125.36%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 88.75% -59.30% -124.77%
Invested Capital Q/Q Growth		 0.00% 0.00% 46.67% -52.35% -62.25% -0.30%
Profitability Metrics		 - - - - - -
EBITDA Margin		 -122.97% 6.26% -47.99% -23.09% -16.84% -3.46%
EBIT Margin		 -127.75% -7.67% -44.52% -22.98% -16.73% -3.37%
Profit (Net Income) Margin		 -127.77% -18.67% -40.02% -30.71% -16.99% -3.14%
Tax Burden Percent		 100.01% 243.28% 89.88% 133.61% 101.57% 93.06%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -153.68% -29.34% -33.98% -10.31%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -270.92% -131.45% -93.73% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% -160.74% -46.44% -32.35% 0.00%
Return on Equity (ROE)		 2,063,053.71% 164.86% -314.42% -75.78% -66.34% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -178.24% -20.27% 33.63% -27.76%
Operating Return on Assets (OROA)		 -362,436.97% -41.94% -107.37% -28.89% -30.46% -8.03%
Return on Assets (ROA)		 -362,482.81% -102.03% -96.51% -38.60% -30.94% -7.47%
Return on Common Equity (ROCE)		 2,063,053.71% 614.86% 68.69% -75.45% -66.34% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 22.10% -109.78% -95.15% -74.50% -12.61%
Net Operating Profit after Tax (NOPAT)		 -255 -39 -458 -178 -147 -32
NOPAT Margin		 -89.43% -5.37% -31.16% -16.09% -11.71% -2.36%
Net Nonoperating Expense Percent (NNEP)		 0.00% 152.73% 117.24% 102.11% 59.74% 0.00%
SG&A Expenses to Revenue		 32.19% 9.75% 17.73% 25.21% 20.48% 16.96%
Operating Expenses to Revenue		 227.75% 107.67% 144.52% 122.98% 116.73% 103.37%
Earnings before Interest and Taxes (EBIT)		 -364 -56 -654 -254 -210 -46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -350 46 -705 -255 -211 -47
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.92 1.24 1.62 4.63
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.95 1.32 1.64 4.67
Price to Revenue (P/Rev)		 2.53 2.38 1.07 0.40 0.37 1.15
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 2.13 0.80 1.21 4.06
Enterprise Value to Revenue (EV/Rev)		 2.53 3.04 0.92 0.42 0.28 1.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 48.58 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 39.72
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 2.39 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 -0.77 0.18 0.62 0.00 0.00
Long-Term Debt to Equity		 0.00 -0.64 0.04 0.00 0.00 0.00
Financial Leverage		 0.00 -0.77 0.59 0.35 0.35 0.00
Leverage Ratio		 -5.69 -1.62 3.26 1.96 2.14 1.83
Compound Leverage Factor		 -5.69 -1.62 3.26 1.96 2.14 1.83
Debt to Total Capital		 0.00% -332.76% 14.92% 38.35% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% -54.42% 11.78% 38.35% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% -278.35% 3.15% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% -1,181.40% 0.62% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 1,614.17% 84.46% 61.65% 100.00% 100.00%
Debt to EBITDA		 0.00 2.78 -0.13 -0.87 0.00 0.00
Net Debt to EBITDA		 0.00 0.76 0.31 -0.07 0.00 0.00
Long-Term Debt to EBITDA		 0.00 2.33 -0.03 0.00 0.00 0.00
Debt to NOPAT		 0.00 -3.24 -0.21 -1.25 0.00 0.00
Net Debt to NOPAT		 0.00 -0.89 0.47 -0.10 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -2.71 -0.04 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% -272.96% 121.85% 0.44% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -1.03 -1,130 -123 145 -87
Operating Cash Flow to CapEx		 -695,108.70% -17,099.28% -39,049.24% -4,565.17% -24,770.89% 2,239.40%
Free Cash Flow to Firm to Interest Expense		 0.00 -0.03 -353.86 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -6.90 -3.29 -88.42 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -6.91 -3.31 -88.65 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 2,837.01 5.47 2.41 1.26 1.82 2.38
Fixed Asset Turnover		 0.00 0.00 672.99 275.07 231.81 263.87
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.02 -38 634 579 286 341
Invested Capital Turnover		 -16,146.73 -38.21 4.93 1.82 2.90 4.37
Increase / (Decrease) in Invested Capital		 0.00 -38 672 -55 -293 55
Enterprise Value (EV)		 720 2,222 1,352 462 348 1,384
Market Capitalization		 720 1,736 1,565 444 464 1,578
Book Value per Share		 $0.00 ($5.96) $1.27 $0.75 $0.59 $0.68
Tangible Book Value per Share		 $0.00 ($6.00) $1.26 $0.70 $0.58 $0.67
Total Capital		 -0.02 -38 634 579 286 341
Total Debt		 0.00 127 95 222 0.00 0.00
Total Long-Term Debt		 0.00 106 20 0.00 0.00 0.00
Net Debt		 0.00 35 -216 18 -116 -195
Capital Expenditures (CapEx)		 0.02 0.69 0.72 4.47 0.58 1.56
Net Nonoperating Expense (NNE)		 109 97 130 162 66 11
Net Nonoperating Obligations (NNO)		 0.00 127 95 222 0.00 0.00
Total Depreciation and Amortization (D&A)		 14 102 -51 -1.19 -1.42 -1.14
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.32) ($1.42) ($0.71) ($0.44) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 406.32M 412.92M 476.24M 482.18M 490.02M
Adjusted Diluted Earnings per Share		 $0.00 ($0.32) ($1.42) ($0.71) ($0.44) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 406.32M 412.92M 476.24M 482.18M 490.02M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.32) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 130.11M 473.27M 479.55M 495.29M 510.91M
Normalized Net Operating Profit after Tax (NOPAT)		 -253 -39 -458 -194 -129 -32
Normalized NOPAT Margin		 -88.71% -5.37% -31.16% -17.57% -10.27% -2.35%
Pre Tax Income Margin		 -127.75% -7.67% -44.52% -22.98% -16.73% -3.37%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -15.71 -1.56 -204.79 0.00 0.00 0.00
NOPAT to Interest Expense		 -10.99 -1.09 -143.35 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -15.71 -1.58 -205.02 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -11.00 -1.11 -143.58 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.70% -0.04% -1.87% -2.92% -42.46%

Quarterly Metrics and Ratios for Clover Health Investments

This table displays calculated financial ratios and metrics derived from Clover Health Investments' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 100.45% -443.14% -63.67% -62.12% -64.23% 120.77% 7.60% 11.28% 8.16% 9.52%
EBITDA Growth		 49.45% 99.47% -10.70% 74.48% 54.60% -4,979.69% 71.55% 124.81% 73.86% 68.46%
EBIT Growth		 49.57% 100.63% -5.57% 72.32% 55.47% -5,890.02% 70.93% 124.88% 73.87% 68.39%
NOPAT Growth		 49.57% 100.89% -5.57% 72.32% 55.47% -4,153.01% 70.93% 135.55% 73.87% 68.39%
Net Income Growth		 -118.64% 55.01% 3.82% 72.39% 45.07% 16.33% 73.60% 125.71% 77.92% 68.65%
EPS Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 325.27% -161.14% 238.55% 235.75% -118.48% -23.27% -67.18% -15.83% 366.15% 66.74%
Free Cash Flow Firm Growth		 -420.25% 106.99% 168.08% 153.81% 151.79% 336.23% -35.28% -23.48% -5.15% -128.47%
Invested Capital Growth		 181.09% -8.68% -53.73% -47.04% -37.55% -50.53% -73.34% -65.57% -54.90% 19.12%
Revenue Q/Q Growth		 1.22% -273.14% 121.74% -0.58% -4.41% 0.53% 12.61% 2.83% -7.09% 1.81%
EBITDA Q/Q Growth		 27.19% 98.23% -6,074.23% 67.97% -29.53% -98.29% 65.42% 127.93% -236.50% -139.24%
EBIT Q/Q Growth		 27.65% 101.55% -6,900.17% 63.76% -16.39% -101.87% 65.86% 131.02% -222.23% -144.14%
NOPAT Q/Q Growth		 27.65% 102.22% -4,860.12% 63.76% -16.39% -101.87% 65.86% 144.31% -185.56% -144.14%
Net Income Q/Q Growth		 27.67% -11.57% 13.80% 60.31% -43.92% -69.94% 72.80% 138.64% -223.58% -141.31%
EPS Q/Q Growth		 27.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 359.52% -305.96% 137.75% -32.72% -135.32% -1,274.19% 110.05% 72.57% 11.68% -271.71%
Free Cash Flow Firm Q/Q Growth		 45.03% 106.72% 2,068.75% -32.86% -47.09% -43.37% 221.77% -20.63% -34.42% -117.00%
Invested Capital Q/Q Growth		 -31.81% -52.35% 89.51% -14.00% -19.58% -62.25% 2.12% 11.08% 5.32% -0.30%
Profitability Metrics		 - - - - - - - - - -
EBITDA Margin		 -8.83% 0.00% -25.68% -8.27% -11.21% -22.11% -6.79% 1.84% -2.71% -6.37%
EBIT Margin		 -8.82% 0.00% -24.75% -9.02% -10.98% -22.06% -6.69% 2.02% -2.65% -6.37%
Profit (Net Income) Margin		 -8.82% 0.00% -22.55% -9.00% -13.55% -22.91% -5.53% 2.08% -2.77% -6.56%
Tax Burden Percent		 100.00% -7,186.52% 91.10% 99.76% 123.36% 103.85% 82.74% 103.08% 104.21% 103.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -22.64% 0.00% -5.41% -0.08% 0.00% -44.81% -8.63% 4.19% -4.53% -19.46%
ROIC Less NNEP Spread (ROIC-NNEP)		 -28.01% 0.00% -6.68% -0.95% 0.00% -65.51% -9.39% 4.26% -5.90% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -29.36% 0.00% -21.81% -2.47% 0.00% -22.61% -11.81% 3.98% -3.88% 0.00%
Return on Equity (ROE)		 -52.00% 0.00% -27.22% -2.54% -63.63% -67.42% -20.43% 8.17% -8.41% 0.00%
Cash Return on Invested Capital (CROIC)		 -132.65% -20.27% 63.04% 52.11% 36.23% 33.63% 100.34% 84.58% 63.90% -27.76%
Operating Return on Assets (OROA)		 -21.22% 0.00% -6.48% -0.09% 0.00% -40.16% -8.06% 2.75% -4.16% -15.15%
Return on Assets (ROA)		 -21.22% 0.00% -5.91% -0.09% 0.00% -41.71% -6.67% 2.83% -4.33% -15.61%
Return on Common Equity (ROCE)		 -51.75% 0.00% -27.22% -2.54% -63.63% -67.42% -20.43% 8.17% -8.41% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -112.90% 0.00% -104.20% -79.00% -70.57% 0.00% -54.68% -38.08% -26.71% 0.00%
Net Operating Profit after Tax (NOPAT)		 -53 1.17 -56 -20 -24 -48 -16 7.19 -6.15 -15
NOPAT Margin		 -6.18% 0.00% -17.33% -6.32% -7.69% -15.44% -4.68% 2.02% -1.86% -4.46%
Net Nonoperating Expense Percent (NNEP)		 5.37% 53.94% 1.27% 0.87% 2.85% 20.69% 0.76% -0.07% 1.38% 0.00%
SG&A Expenses to Revenue		 8.20% 0.00% 21.42% 19.50% 19.79% 21.18% 17.09% 15.58% 16.62% 18.62%
Operating Expenses to Revenue		 108.82% 0.00% 124.75% 109.02% 110.98% 122.06% 106.69% 97.98% 102.65% 106.37%
Earnings before Interest and Taxes (EBIT)		 -75 1.17 -80 -29 -34 -68 -23 7.19 -8.79 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -76 -1.34 -83 -26 -34 -68 -24 6.57 -8.97 -21
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.07 1.24 1.25 1.31 1.63 1.62 1.34 1.88 4.10 4.63
Price to Tangible Book Value (P/TBV)		 2.09 1.32 1.34 1.39 1.73 1.64 1.36 1.90 4.14 4.67
Price to Revenue (P/Rev)		 0.27 0.40 0.75 26.33 0.00 0.37 0.31 0.46 1.05 1.15
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.02 0.80 0.83 0.69 0.81 1.21 0.63 1.09 3.26 4.06
Enterprise Value to Revenue (EV/Rev)		 0.41 0.42 1.68 39.80 0.00 0.28 0.14 0.27 0.83 1.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 26.72 0.00 0.00 0.00 0.00 0.00 39.72
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.83 0.92 1.71 2.39 0.26 0.66 3.17 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 2.10 0.62 2.40 1.85 1.36 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 1.05 0.35 3.27 2.60 1.76 0.35 1.26 0.94 0.66 0.00
Leverage Ratio		 3.12 1.96 5.08 4.38 3.67 2.14 3.45 2.95 2.58 1.83
Compound Leverage Factor		 3.12 1.96 5.08 4.38 3.67 2.14 3.45 2.95 2.58 1.83
Debt to Total Capital		 67.74% 38.35% 70.55% 64.96% 57.58% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 66.09% 38.35% 70.55% 64.96% 57.58% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 32.26% 61.65% 29.45% 35.04% 42.42% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.63 -0.87 -2.95 -3.29 -3.02 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -0.85 -0.07 -1.92 -1.19 -0.61 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -2.66 -1.25 -4.28 -4.79 -4.43 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -1.38 -0.10 -2.78 -1.73 -0.89 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -836 56 1,218 818 433 245 788 626 410 -70
Operating Cash Flow to CapEx		 39,249.03% -5,400.26% 31,486.85% 15,020.62% -7,728.81% 0.00% 5,828.09% 11,273.80% 12,527.82% -27,248.57%
Free Cash Flow to Firm to Interest Expense		 -2,068.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 251.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 250.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 2.41 1.26 0.26 0.01 0.00 1.82 1.20 1.36 1.57 2.38
Fixed Asset Turnover		 1,285.02 275.07 157.89 4.70 0.00 231.81 262.46 266.15 270.76 263.87
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 1,215 579 1,097 943 759 286 292 325 342 341
Invested Capital Turnover		 3.67 1.82 0.31 0.01 0.00 2.90 1.84 2.08 2.44 4.37
Increase / (Decrease) in Invested Capital		 783 -55 -1,274 -838 -456 -293 -805 -619 -417 55
Enterprise Value (EV)		 1,240 462 908 654 611 348 184 355 1,114 1,384
Market Capitalization		 812 444 405 433 524 464 393 611 1,403 1,578
Book Value per Share		 $0.82 $0.75 $0.67 $0.68 $0.66 $0.59 $0.59 $0.65 $0.69 $0.68
Tangible Book Value per Share		 $0.81 $0.70 $0.63 $0.64 $0.62 $0.58 $0.58 $0.65 $0.68 $0.67
Total Capital		 1,215 579 1,097 943 759 286 292 325 342 341
Total Debt		 823 222 774 613 437 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 428 18 503 222 88 -116 -209 -255 -289 -195
Capital Expenditures (CapEx)		 0.26 3.88 0.25 0.35 0.24 -0.26 0.45 0.40 0.40 0.32
Net Nonoperating Expense (NNE)		 23 85 17 8.60 18 23 2.95 -0.22 3.01 7.08
Net Nonoperating Obligations (NNO)		 823 222 774 613 437 0.00 0.00 0.00 0.00 0.00
Total Depreciation and Amortization (D&A)		 -0.07 -2.51 -2.98 2.40 -0.69 -0.16 -0.35 -0.62 -0.18 -0.01
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.16) $0.00 ($0.15) ($0.06) ($0.09) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 477.69M 476.24M 478.81M 479.16M 480.77M 482.18M 486.37M 487.48M 490.18M 490.02M
Adjusted Diluted Earnings per Share		 ($0.16) $0.00 ($0.15) ($0.06) ($0.09) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 477.69M 476.24M 478.81M 479.16M 480.77M 482.18M 486.37M 495.18M 490.18M 490.02M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 477.94M 479.55M 482.65M 484.86M 487.64M 495.29M 1.05B 497.47M 501.11M 510.91M
Normalized Net Operating Profit after Tax (NOPAT)		 -53 0.82 -55 -17 -23 -46 -16 5.36 -6.53 -15
Normalized NOPAT Margin		 -6.18% 0.00% -16.93% -5.28% -7.39% -15.00% -4.61% 1.51% -1.97% -4.46%
Pre Tax Income Margin		 -8.82% 0.00% -24.75% -9.02% -10.98% -22.06% -6.69% 2.02% -2.65% -6.37%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -186.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -130.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -187.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -131.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.43% -1.87% -1.01% -1.42% -2.39% -2.92% -4.13% -7.60% -13.45% -42.46%

Frequently Asked Questions About Clover Health Investments' Financials

When does Clover Health Investments's financial year end?

According to the most recent income statement we have on file, Clover Health Investments' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Clover Health Investments' net income changed over the last 5 years?

Clover Health Investments' net income appears to be on a downward trend, with a most recent value of -$43.01 million in 2024, falling from -$363.74 million in 2019. The previous period was -$213.36 million in 2023.

How has Clover Health Investments revenue changed over the last 5 years?

Over the last 5 years, Clover Health Investments' total revenue changed from $284.68 million in 2019 to $1.37 billion in 2024, a change of 381.5%.

How much debt does Clover Health Investments have?

Clover Health Investments' total liabilities were at $239.60 million at the end of 2024, a 15.7% decrease from 2023, and a 202,989.6% increase since 2019.

How much cash does Clover Health Investments have?

In the past 5 years, Clover Health Investments' cash and equivalents has ranged from $0.00 in 2019 to $299.97 million in 2021, and is currently $194.54 million as of their latest financial filing in 2024.

How has Clover Health Investments' book value per share changed over the last 5 years?

Over the last 5 years, Clover Health Investments' book value per share changed from 0.00 in 2019 to 0.68 in 2024, a change of -340,500.0%.


Related Companies

This page (NASDAQ:CLOV) was last updated on 4/21/2025 by MarketBeat.com Staff
From Our Partners
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...
Colonial Metals | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...
Stansberry Research | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored